Replies to post #555465 on NorthWest Biotherapeutics Inc (NWBO)

[hoffmann6383]

I was also unnerved by LP referring to Advent as an asset, which makes me concerned that the earlier speculation of NWBO acquiring Advent as a real possibility. Which would of course be a vehicle for another share grab by Toucan.

It makes absolutely no sense to acquire advent. Advent is an asset for NWBO because they essentially control a well run CDMO.

have a good one PM.

[jfr1611]

PM, did you speak with the company lately?
FYI, they’ve never been in better financial shape.
Before going out and speculating, do your work and call them.

[churchill_21]

Nailed it, PM. And to think they scheduled the meeting at the 11th hour of 2022. They had ample time to prepare for this ASM, to provide a few solid projections, or some semblance of direction. No, it came across as if they are haphazardly building the plane while they fly. Even if they are learning the approval process as they go along (fine, DCVax is a novel treatment), the call was a missed opportunity all around and at times insulting. I would rather LP just say things are on track and ended the call. Science great. Leadership, not so much, but what do you expect with OTC.

Again, to suggest they could have approval in 4 to 6 months as some have suggested (pipe dream), is just comical. Assuming they did, I guess Linda can just add another role to her title salad...guessing CCO or SVP of Sales and Marketing.

[no2koolaid]

As to this...

I was also unnerved by LP referring to Advent as an asset, which makes me concerned that earlier speculation of NWBO acquiring Advent as a real possibility.

If one reads any transcripts of the conference calls of large businesses, executives always refer to their relationships with key suppliers, distributors and partners as assets. There is nothing "unnerving" about that. Perhaps just a projection of ungrounded fear.